ADC Therapeutics
ADCT
ADC Therapeutics (ADCT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.11
- EPS estimate
- −$0.22
- EPS surprise
- +49.07%
- Revenue surprise
- +1.91%
- Revenue
- $19.2M
- Revenue estimate
- $18.9M
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | −$0.22 | −$0.11 | +49.07% | $19.2M | SEC |
| Q1 2026 | May 4, 2026 | −$0.20 | −$0.21 | −4.12% | $20.9M | SEC |
| Q4 2025 | Mar 10, 2026 | −$0.27 | −$0.04 | +85.09% | $23.1M | SEC |
| Q3 2025 | Nov 10, 2025 | −$0.36 | −$0.30 | +17.42% | $16.4M | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.49 | −$0.50 | −1.63% | $18.8M | SEC |
| Q1 2025 | May 14, 2025 | −$0.40 | −$0.36 | +10.74% | $23.0M | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.41 | −$0.29 | +29.56% | $16.9M | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.40 | −$0.42 | −6.33% | $18.5M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.46 | −$0.38 | +16.89% | $17.4M | SEC |
| Q1 2024 | May 6, 2024 | −$0.56 | −$0.56 | −0.76% | $18.1M | SEC |
| Q4 2023 | Mar 13, 2024 | −$0.50 | −$1.03 | −105.14% | $16.8M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.63 | −$0.58 | +8.52% | $14.5M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.70 | −$0.58 | +17.10% | $19.3M | SEC |
| Q1 2023 | May 9, 2023 | −$0.02 | −$0.74 | −3600.00% | $19.0M | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.48 | −$0.30 | +37.93% | $69.8M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.35 | −$0.65 | −84.19% | $76.3M | — |
| Q2 2022 | Aug 9, 2022 | −$0.80 | −$0.84 | −5.22% | $17.3M | — |
| Q1 2022 | May 9, 2022 | −$0.67 | −$0.22 | +67.33% | $46.5M | — |
| Q4 2021 | Mar 3, 2022 | −$0.85 | −$0.45 | +46.79% | $17.0M | — |
| Q3 2021 | Nov 2, 2021 | −$0.92 | −$0.93 | −1.41% | $13.1M | — |
Quarterly revenue
Frequently asked questions
When did ADC Therapeutics (ADCT) last report earnings?
ADC Therapeutics last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did ADCT beat earnings estimates?
Yes. ADC Therapeutics reported EPS of −$0.11 for Q2 2026 against a −$0.22 estimate — a 49.07% beat.
How much revenue did ADCT report last quarter?
ADC Therapeutics reported $19.2M in revenue for Q2 2026, against a consensus estimate of $18.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.